Sepsis News and Research

Latest Sepsis News and Research

Common cytokine profile in ARDS, severe COVID-19 and sepsis

Many lives have been lost to the severe pneumonic disease COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during the ongoing pandemic. The reason for the critical lung injury that results in a fatal outcome in a significant minority of patients has been supposed to be the dramatic oversecretion of pro-inflammatory cytokines and chemokines triggered by the virus.

19 May 2020

University of Greenwich develops compounds that can fight COVID-19 killer

Covid-19 treatment that could potentially also help protect cancer and organ transplant patients is being developed at the University of Greenwich.

15 May 2020

Chasing the elusive dream of a COVID cure

Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.

15 May 2020

High DPP3 concentration in the blood predicts multiple organ failure in burn patients

Diagnostics company SphingoTec GmbH ("sphingotec") and 4TEEN4 Pharmaceuticals GmbH ("4TEEN4") announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients.

15 May 2020

Anti-inflammatory drug may improve respiratory function in some severe COVID-19 cases

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients with severe coronavirus disease 2019 (COVID-19).

14 May 2020

Low albumin levels could predict poor outcome in COVID-19

A Spanish study has revealed that COVID-19 patients who have a low level of albumin have a poorer outcome compared to those with normal levels of blood albumin. The study titled, “Low albumin levels are associated with poorer outcomes in a case series of COVID-19 patients in Spain: a retrospective cohort study,” was released prior to peer-review on the open-access preprint server site Medrxiv*.

13 May 2020

UCI Health to initiate clinical trial of a drug to treat critically ill COVID-19 patients

UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve.

13 May 2020

Scientists discover how the iron chelator drives immune system to deal with TB

Although COVID-19 commands the headlines today, tuberculosis (TB) remains the biggest infection killer in the world and multiple drug resistant TB, which does not respond to regular antibiotics, continues to be a major threat to global health.

13 May 2020

Researchers launch clinical trial to test the efficacy of antidepressant against COVID-19

An antidepressant medication is being tested as a potential treatment for COVID-19 after University of Virginia School of Medicine researchers determined it may prevent dangerous overreactions by the immune system.

13 May 2020

Platelets can intensify inflammatory processes, study shows

Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

12 May 2020

‘No intubation’: Seniors fearful of COVID-19 are changing their living wills

Last month, Minna Buck revised a document specifying her wishes should she become critically ill.

12 May 2020

Study demonstrates dynamic and broad-scale immune alterations in COVID-19 patient

A new case report released on the preprint server medRxiv* provides a detailed longitudinal analysis of the immune response associated with a fatal case of coronavirus disease (COVID-19). It highlights the need for addressing the source of hyper inflammation in the treatment approach.

10 May 2020

New antibiotic guidelines could save more lives in intensive care units

More lives could be saved in intensive care units around the world if new antibiotic guidelines designed by The University of Queensland are adopted.

8 May 2020

Modified dialysis device treats COVID-19

As part of a randomized controlled trial, a team from Lawson Health Research Institute is the first in the world to treat a patient with COVID-19 using a modified dialysis device.

7 May 2020

IONTAS announces a new collaboration to identify novel immunotherapy targets

Antibody discovery agreement will support the development of new therapeutics for acute and chronic inflammatory syndromes.

From IONTAS 7 May 2020

AI-enabled precision medicine may increase survival rate of patients with COVID-19-related sepsis

Data scientists from UK-headquartered AI precision medicine company, PrecisionLife, have used the Company’s proprietary AI enabled precision medicine platform to identify 59 repurposing drug candidates that could be used to develop new therapeutic strategies to increase the survival rate of patients who develop sepsis while suffering from severe COVID-19.

7 May 2020

Cytokine storms created by COVID-19 could be reduced by using blood filter

Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.

6 May 2020

Universal childhood vaccination could prevent antimicrobial resistance

A new study from the University of California, Berkeley, published in the journal Nature in April 2020, reports that extending vaccination to all children could help resolve antimicrobial resistance - one of the biggest obstacles to effective healthcare in low-income countries. This is the first study to look at how vaccination is related to the use of antibiotics in low- and middle-income countries.

29 Apr 2020

Venatorx and GARDP collaborate to accelerate development of new antibiotic

Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) today announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam (formerly cefepime/VNRX-5133).

29 Apr 2020

Researchers test existing anti-inflammatory drug in COVID-19 patients

An anti-inflammatory drug developed at Scripps Research 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19, the pandemic disease caused by the novel coronavirus.

29 Apr 2020